low dose and high potency applications

State-of-the art containment and isolation procedures are in place throughout our development and manufacturing network, accommodating end-to-end solutions from HPAPI to drug product.

Our Bend OR, Quakertown PA and Monteggio CH sites have leading commercial capacity for producing HPAPI drug product intermediates based on particle size reduction or spray drying technologies. Our Stein, CH and Basel, CH facilities provide parenteral product development and sterile fill / finish services for non-oral applications. Our PIC and PIB drug products are produced at our Tampa FL site, with both non-GMP development and GMP manufacturing encapsulation and bottle-fill capabilities.

Our solid oral drug product technologies, which are based on either liquid-filled hard capsules, improving product dose uniformity facilitated by highly accurate liquid fill metering, minimizing product cross-contamination, increasing operator safety through reducing potential exposure, reducing processing time and costs, increasing fill speeds, removing the risk of fire or explosion due to dusting and improving the overall ease of handling.

We utilize flexible high containment handling capability and facilities for a wide range of compound types and safety classifications, ranging from biologics and small molecules to oral to inhalation and parenteral delivery routes. We can typically accommodate HPAPIs to OEB5. Our co-located product development and manufacturing sites are also equipped to handle other challenging compounds, including controlled substances, hormones and cytotoxics.

Our broad capabilities and integrated approach enable you to use one partner throughout your project, from development through to manufacturing. This reduces risk, complexity, and time to bring your HPAPI product to market.

Our facilities have phase-appropriate processing equipment in place, allowing us to deliver services tailored to the development stage of your HPAPI project.